This page separates reported trial information from statistical interpretation. The ClinicalTrials.gov record reports that results have been posted, but it does not provide statistical analyses in the ClinicalTrials.gov record.
1. Trial at a Glance
MONARCH 1 was a phase 2, single-group study of abemaciclib in participants with previously treated metastatic breast cancer. The study enrolled 132 participants and evaluated a binary primary endpoint: the percentage of participants achieving complete response or partial response, defined as objective response rate (ORR).
| Feature | MONARCH 1 |
|---|---|
| Trial name | MONARCH 1 |
| ClinicalTrials.gov identifier | NCT02102490 |
| Phase | Phase 2 |
| Condition | Metastatic Breast Cancer |
| Population | Participants with previously treated breast cancer that has spread |
| Allocation | NA |
| Design model | Single group |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 132 |
| Intervention | Abemaciclib |
| Primary endpoint type | Binary |
| Primary endpoints registered | 1 |
| Outcome measures posted | 9 |
| Trial status | Completed |
| Lead sponsor | Eli Lilly and Company |
| Sponsor type | Industry |
| Start | 2014-06-10 |
| Primary completion | 2016-04-30 |
2. Clinical Question
The primary clinical question was descriptive rather than a randomized treatment-versus-control comparison: among participants with previously treated metastatic breast cancer who received abemaciclib, what percentage achieved a complete response or partial response under the registered response criteria?
Population
Participants with previously treated breast cancer that has spread, described in the registry as metastatic breast cancer.
Intervention
Abemaciclib.
Comparator
There was no comparator arm. The registry design model is single group and masking is none.
Primary question
What proportion of participants achieved a best overall response of complete response or partial response?
This distinction is central to the statistical interpretation. A single-group study can estimate an observed response proportion and its uncertainty, but it cannot, by itself, estimate a randomized between-treatment effect.
3. Trial Design
Abemaciclib
- Intervention: abemaciclib
- Single-group phase 2 design
- No comparator arm
- No masking
No comparator group
- The registry does not identify a control intervention.
- There is therefore no randomized treatment contrast.
- Observed response is interpreted within the single treated cohort.
4. Trial Timeline
Study start
The registered study start date was June 10, 2014.
Primary completion
The registered primary completion date was April 30, 2016.
Completed
The ClinicalTrials.gov record identifies the trial as completed and indicates that results have been posted.
5. Primary Endpoint
| Endpoint | Registered definition | Time frame | Type |
|---|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions. | From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months) | Binary |
Why the endpoint is binary
For each participant, the primary endpoint ultimately classifies whether the participant achieved the registered response category of CR or PR. At the participant level, this creates a binary outcome: response or no response under the endpoint definition.
The registry defines ORR as a percentage. The statistical uncertainty around an observed proportion would ordinarily be summarized with a confidence interval, with the exact interval method chosen in accordance with the statistical analysis plan.
6. Planned Analysis
The ClinicalTrials.gov record indicates that results have been posted for the primary endpoint, but the ClinicalTrials.gov record contains no formal statistical analyses. Consequently, there is no reported formal statistical comparison, confidence interval, p-value, or model-based treatment effect in the ClinicalTrials.gov record.
How this endpoint would normally be analyzed
For a binary response endpoint in a single-group phase 2 study, the analysis would typically begin with the number and percentage of participants achieving the defined response. A confidence interval for the response proportion would quantify sampling uncertainty. Depending on the prespecified statistical plan, a one-sample hypothesis test could also compare the observed response proportion with a historically specified benchmark.
Such a benchmark is not reported in the ClinicalTrials.gov record. Therefore, this page does not introduce a null response rate, calculate a p-value, or infer one from the study design.
What can be estimated
The observed percentage of participants meeting the CR-or-PR definition, together with an appropriate confidence interval if the required response counts are available.
What cannot be inferred
A causal treatment effect relative to another therapy cannot be estimated from the single-group design without an external comparison that is explicitly defined and appropriately analyzed.
7. Results Reporting Status
ClinicalTrials.gov identifies the MONARCH 1 results as posted and reports 9 outcome measures. However, the ClinicalTrials.gov record contains no formal statistical analyses for the primary endpoint.
| Result component | Status in the ClinicalTrials.gov record |
|---|---|
| Results posted | Yes |
| Outcome measures posted | 9 |
| Primary endpoint result identified | Yes |
| Formal statistical analyses reported | None |
| Formal p-value reported | None |
| Confidence interval posted on ClinicalTrials.gov for the primary analysis | None |
| Randomized treatment comparison | Not applicable to the single-group design |
8. Safety
the ClinicalTrials.gov record reports serious adverse events by arm as 33/132 for the abemaciclib group.
| Safety measure | Abemaciclib |
|---|---|
| Serious adverse events | 33/132 affected / at risk |
Because MONARCH 1 has one treatment group, this safety result is descriptive. There is no randomized comparator rate in the ClinicalTrials.gov record against which the serious-adverse-event frequency can be contrasted.
The reported numerator and denominator identify the number affected and the number at risk. The ClinicalTrials.gov record does not provide a confidence interval or formal hypothesis test for this safety proportion.
9. Statistical Methodology
Binary endpoint analysis
The primary endpoint is explicitly identified as binary. Each participant contributes to the response classification according to whether the best overall response is CR or PR under RECIST v1.1.
For a single-group study, the most direct estimator is a sample proportion. If x participants respond among n analyzed participants, the observed response rate is:
The estimate describes the observed proportion in this study cohort. It is not a randomized estimate of the difference between abemaciclib and another treatment.
Confidence intervals for a proportion
A confidence interval would quantify uncertainty caused by sampling variability. For a binary endpoint, exact binomial or other prespecified binomial-based methods can be used. The appropriate method should be taken from the trial's statistical analysis plan when available.
The important distinction is that a confidence interval around an observed response rate answers a precision question: how uncertain is the estimated proportion? It does not establish that the intervention caused the observed responses.
Historical-control comparisons
A single-group phase 2 study can sometimes be designed around a historical benchmark. In that setting, the statistical question is whether the observed response proportion is sufficiently different from a prespecified reference value.
No historical benchmark is provided in the ClinicalTrials.gov record. Accordingly, this page does not create one or use an external response rate as a substitute.
RECIST-based response classification
The registered endpoint uses RECIST v1.1 and defines the response categories that determine the binary outcome. This is important statistically because the response rate is only meaningful in relation to the operational definition used to classify participants.
Time window for response assessment
The registered primary endpoint is assessed from the date of first dose until disease progression or death due to any cause, with a stated time frame of up to 14 months. The time frame therefore defines the observation window attached to the endpoint rather than a median survival estimate.
10. Statistical Methods Explained
Why is the primary endpoint analyzed as a proportion?
The registered primary endpoint classifies participants according to whether they achieved CR or PR. That creates a binary outcome, so the natural summary is the proportion of participants meeting the response definition.
What does ORR actually measure?
ORR measures the percentage of participants whose best overall response meets the registered CR-or-PR definition. It does not measure the average amount of tumor shrinkage across all participants, nor does it directly measure time to progression or survival.
Why does the single-group design matter?
With only one treatment group, there is no randomized counterfactual group. The observed response proportion therefore describes what occurred among participants receiving abemaciclib, but it does not isolate how much of that outcome would differ from what would have occurred under another treatment.
Why would a confidence interval be useful?
A response percentage calculated from 132 participants is an estimate based on a finite sample. A confidence interval provides a quantitative description of uncertainty around that estimate. A narrow interval would indicate greater statistical precision than a wide interval, all else equal.
Why is a p-value not automatically available?
A p-value requires a specified null hypothesis and an analysis procedure. For example, a one-sample binomial test could compare an observed response rate with a prespecified historical benchmark. The ClinicalTrials.gov record does not provide such a benchmark or a statistical-analysis entry, so a p-value cannot be responsibly reconstructed from the ClinicalTrials.gov record.
What does the 14-month time frame mean?
The registry specifies that the primary response endpoint is assessed from first dose until disease progression or death due to any cause, up to 14 months. This is an endpoint observation window; it is not a statement that participants had a median response duration of 14 months.
Can the 33/132 serious-adverse-event result be compared with efficacy?
Not directly. Serious adverse events and objective response are different outcome domains. One describes a safety event category and the other describes tumor response. A statistical analysis should keep efficacy and safety estimands separate rather than combine them into a single numerical judgment.
11. Interpreting a Single-Group Phase 2 Study
A single-group phase 2 study is structurally different from a randomized controlled trial. Its principal statistical strength is the ability to characterize outcomes within a defined treated cohort. Its principal limitation for causal inference is the absence of a concurrent randomized comparison group.
An observed ORR would describe the proportion of participants in MONARCH 1 who achieved CR or PR under the registered RECIST v1.1 definition during the specified observation period. It would not by itself establish that abemaciclib produces the same response proportion in every population or that the response rate exceeds that of another therapy.
A 95% confidence interval, if reported using a prespecified method, would quantify statistical uncertainty around the estimated response proportion. It would not describe the range of responses experienced by individual participants.
If a formal one-sample hypothesis test had been prespecified, its p-value would quantify how incompatible the observed data were with the specified null hypothesis under the chosen statistical model. It would not measure the size or clinical importance of the observed response rate.
12. Limitations
- No randomized comparator: the single-group design does not provide a concurrent randomized control group for estimating a treatment difference.
- No formal statistical analyses in the ClinicalTrials.gov record: no formal statistical analyses were posted, so confidence intervals and p-values cannot be reported without importing information from outside the registry record.
- Historical comparisons require caution: comparing a single-group response rate with an external historical response rate can introduce differences in patient selection, disease characteristics, assessment procedures, follow-up, and other factors.
- Response is not survival: ORR captures tumor response but does not by itself quantify overall survival or another time-to-event outcome.
- Assessment window matters: the registered primary endpoint is tied to a specific period extending from first dose through disease progression or death due to any cause, up to 14 months.
- Single-group safety is descriptive: the reported 33/132 serious-adverse-event figure does not establish comparative safety because no control-arm rate is available in the ClinicalTrials.gov record.
- Generalizability: the enrolled study population may not represent every patient with metastatic breast cancer, and the ClinicalTrials.gov record does not provide a complete baseline-characteristic table with which to assess representativeness.
13. Why This Trial Matters Statistically
MONARCH 1 is a useful teaching example because it illustrates how statistical interpretation changes when a phase 2 study uses a single-group design rather than randomization.
| Concept | How it appears in MONARCH 1 |
|---|---|
| Single-group design | One study group received abemaciclib. |
| Binary endpoint | The primary endpoint classifies participants according to achievement of CR or PR. |
| Objective response rate | The primary endpoint is the percentage of participants with CR or PR. |
| RECIST v1.1 | Response is defined using RECIST v1.1 criteria. |
| Time window | The primary endpoint is assessed from first dose until disease progression or death due to any cause, up to 14 months. |
| Confidence intervals | An appropriate binomial confidence interval would quantify uncertainty around an observed response proportion if reported. |
| Historical controls | A benchmark could be used in a formal one-sample analysis if prespecified, but no benchmark is reported here. |
| Safety analysis | Serious adverse events are reported descriptively as 33/132 in the abemaciclib group. |
| Causal inference | The absence of a randomized comparator limits direct causal comparison with another treatment. |
| Registry reporting | Results are posted, but no formal statistical analyses were posted. |
14. ClinicalTrials.gov Reporting vs Statistical Interpretation
What the registry tells us
The study is completed, enrolled 132 participants, used a single-group design, evaluated abemaciclib, and registered a binary ORR primary endpoint assessed through disease progression or death due to any cause up to 14 months.
What statistical analysis adds
The statistical perspective explains how a binary response endpoint can be estimated, how uncertainty would normally be quantified, and why a single-group study cannot provide the same treatment-effect interpretation as a randomized comparison.
15. Important Distinction: Response Rate vs Treatment Effect
One of the most important statistical lessons from MONARCH 1 is the distinction between an observed outcome and a comparative treatment effect.
This describes the proportion of participants achieving the prespecified response category.
A comparative estimand requires a defined comparator. MONARCH 1's single-group design does not supply a randomized comparator arm.
This distinction prevents a common interpretive error: treating a high response proportion in a single treatment cohort as if it were itself evidence of a causal advantage over another therapy. The numerical response rate and the causal treatment effect are different statistical quantities.
16. Primary Endpoint Interpretation Framework
| Question | Statistical answer |
|---|---|
| What is measured? | The percentage of participants with a best overall response of CR or PR. |
| What is the unit of analysis? | The individual participant contributes a binary response classification. |
| What is the estimand? | The response proportion within the defined single-group study population and registered assessment window. |
| What provides precision? | A confidence interval for the response proportion. |
| What would provide a formal hypothesis test? | A prespecified null response proportion and a corresponding one-sample test. |
| What would establish a randomized comparative effect? | A concurrent randomized comparator group and a prespecified between-group estimand. |
| What is available here? | The endpoint definition and study design are available; no formal statistical analyses were posted results. |
17. Statistical Concepts in This Trial
Learn more about the methods used in this trial:
18. Related Statistical Calculators
19. Sources
- ClinicalTrials.gov: MONARCH 1, NCT02102490.
- PubMed: Publication indexed under PMID 28533223.
Continue through the Clinical Biostats learning pathway
Explore the statistical concepts behind binary endpoints, response rates, confidence intervals, single-arm studies, and clinical-trial design.
20. Record Summary
MONARCH 1 is a completed phase 2, single-group study of abemaciclib in participants with previously treated metastatic breast cancer. Its registered primary endpoint is the percentage of participants achieving complete response or partial response, defined as objective response rate under RECIST v1.1, assessed from first dose until disease progression or death due to any cause, up to 14 months. The study enrolled 132 participants, and the ClinicalTrials.gov record reports 33 serious-adverse-event cases among 132 participants in the abemaciclib group.
The statistical structure is therefore fundamentally different from that of a randomized comparative trial. The central estimand is an observed binary response proportion within the study cohort. A confidence interval would describe its precision, while a formal one-sample hypothesis test would require a prespecified benchmark. Because no formal statistical analyses were posted, this page does not introduce a response estimate, confidence interval, or p-value that is not present in the ClinicalTrials.gov record.